ResearcherTokai UniversityNo recent work listed
Aya Kawanishi
Matched on OpenAlex author ID A5007253552. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper
Papers 6
- miR-4653-3p overexpression is associated with a poor prognosis of pancreatic ductal adenocarcinoma via HIPK2 downregulation. Co-author DOI 10.1038/s41598-022-22950-2↗
- Low expression of DDX5 is associated with poor prognosis in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jclinpath-2020-207002↗
- Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression g… Co-author DOI 10.1038/s41598-020-74067-z↗
- Cancer-associated fibroblasts are a useful cytological finding for diagnosing pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cyt.12868↗
- Nectin-1 expression in cancer-associated fibroblasts is a predictor of poor prognosis for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00595-017-1618-3↗
- Clinicopathological significance of Necl-4 expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jclinpath-2016-204028↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Kenichi Hirabayashi · 6 shared papers, 2017–2022 · strength 0.65
- Paper miR-4653-3p overexpression is associated with a poor prognosis of pancreatic ductal adenocarcinoma via HIPK2 downregula… DOI 10.1038/s41598-022-22950-2↗
- Paper Low expression of DDX5 is associated with poor prognosis in patients with pancreatic ductal adenocarcinoma. DOI 10.1136/jclinpath-2020-207002↗
- Paper Cancer-associated fibroblasts are a useful cytological finding for diagnosing pancreatic ductal adenocarcinoma. DOI 10.1111/cyt.12868↗
- Naoya Nakamura · 5 shared papers, 2017–2022 · strength 0.55
- Paper miR-4653-3p overexpression is associated with a poor prognosis of pancreatic ductal adenocarcinoma via HIPK2 downregula… DOI 10.1038/s41598-022-22950-2↗
- Paper Low expression of DDX5 is associated with poor prognosis in patients with pancreatic ductal adenocarcinoma. DOI 10.1136/jclinpath-2020-207002↗
- Paper Cancer-associated fibroblasts are a useful cytological finding for diagnosing pancreatic ductal adenocarcinoma. DOI 10.1111/cyt.12868↗
- Toshio Nakagohri · 4 shared papers, 2017–2022 · strength 0.44
- Paper miR-4653-3p overexpression is associated with a poor prognosis of pancreatic ductal adenocarcinoma via HIPK2 downregula… DOI 10.1038/s41598-022-22950-2↗
- Paper Low expression of DDX5 is associated with poor prognosis in patients with pancreatic ductal adenocarcinoma. DOI 10.1136/jclinpath-2020-207002↗
- Paper Nectin-1 expression in cancer-associated fibroblasts is a predictor of poor prognosis for pancreatic ductal adenocarcin… DOI 10.1007/s00595-017-1618-3↗
- Tsubasa Saika · 3 shared papers, 2020–2022 · strength 0.40
- Paper miR-4653-3p overexpression is associated with a poor prognosis of pancreatic ductal adenocarcinoma via HIPK2 downregula… DOI 10.1038/s41598-022-22950-2↗
- Paper Low expression of DDX5 is associated with poor prognosis in patients with pancreatic ductal adenocarcinoma. DOI 10.1136/jclinpath-2020-207002↗
- Paper Cancer-associated fibroblasts are a useful cytological finding for diagnosing pancreatic ductal adenocarcinoma. DOI 10.1111/cyt.12868↗
- Masashi Morimachi · 2 shared papers, 2021–2022 · strength 0.29
- Paper miR-4653-3p overexpression is associated with a poor prognosis of pancreatic ductal adenocarcinoma via HIPK2 downregula… DOI 10.1038/s41598-022-22950-2↗
- Paper Low expression of DDX5 is associated with poor prognosis in patients with pancreatic ductal adenocarcinoma. DOI 10.1136/jclinpath-2020-207002↗
- Masaki Miyazawa · 1 shared paper, 2022 · strength 0.16
- Tetsuya Mine · 2 shared papers, 2017–2018 · strength 0.15
- Misuzu Yamada · 2 shared papers, 2017–2018 · strength 0.15
- Tatehiro Kagawa · 1 shared paper, 2021 · strength 0.13
- Yoko Matsuda · 1 shared paper, 2020 · strength 0.10
- Shinichiro Takahashi · 1 shared paper, 2020 · strength 0.10
- Motohiro Kojima · 1 shared paper, 2020 · strength 0.10
- Mari A. Mino-Kenudson · 1 shared paper, 2020 · strength 0.10
- Tomio Arai · 1 shared paper, 2020 · strength 0.10
- Hideki Izumi · 1 shared paper, 2018 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.